New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 28, 2013
09:26 EDTBBRY, AFAM, GTIV, AMED, PFE, ABFS, SNY, BIIB, ACI, MCP, DNDN, ACN, LHCGOn The Fly: Pre-market Movers
HIGHER: Dendreon (DNDN), up 9.8% after getting positive EU opinion for Provenge drug... Arkansas Best (ABFS), up 10% after ABF Freight System employees represented by Teamsters ratify five-year national labor agreement... Molycorp (MCP), up 7.8% after SEC completes investigation with no enforcement action recommended... Arch Coal (ACI), up 8.9% after announcing will sell non-core Utah operations to Bowie Resources for $435M... Biogen (BIIB), up 5.8% after the European Medicines Agency granted Sanofi's multiple sclerosis drug Aubagio "new active substance" status. Sanofi, which also received a positive CHMP opinion for Lemtrada, up 1.5%... Pfizer (PFE), up 1% after boosting share buyback program by $10B. DOWN AFTER EARNINGS: BlackBerry (BBRY), down 23%... Accenture (ACN), down 9%... Nike (NKE), down 0.8%. ALSO LOWER: Home health agencies, including Amedisys (AMED), down 21%, Gentiva Health (GTIV), down 16%, Almost Family (AFAM), down 13%, and LHC Group (LHCG), down 12%, after the Centers for Medicare & Medicaid Services proposed 2014 reimbursement cuts.
News For BBRY;ACN;DNDN;MCP;ACI;BIIB;SNY;ABFS;PFE;AMED;GTIV;AFAM;LHCG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
October 21, 2014
06:44 EDTSNYActavis among bidders for Omega Pharma, Bloomberg reports
Subscribe for More Information
05:51 EDTBBRYStocks with implied volatility movement; TLM BBRY
Subscribe for More Information
October 20, 2014
11:59 EDTBBRYBlackBerry calls active on Lenovo may make bid report
Blackberry October weekly 10 and 11 calls are active 38K contracts (8K puts) on Lenovo may make $15 per share BlackBerry bid shortly, Benzinga says. October weekly call option implied volatility is at 75, November is at 63, December is at 61; compared to its 26-week average of 56 according to Track Data. Active call volume suggests traders taking positions for large near term price movement.
11:10 EDTBBRYLenovo may make $15 per share BlackBerry bid shortly, Benzinga says
Subscribe for More Information
10:37 EDTSNYSanofi unit announces Aubagio gains FDA approval due to study data
Genzyme, a Sanofi company, announced that the Food and Drug Administration has approved the inclusion of efficacy and safety data from the TOWER and TOPIC studies of once-daily, oral Aubagio in the productís U.S. label. In the TOWER study, patients with relapsing MS receiving Aubagio 14 mg had a statistically significant reduction in annualized relapse rate and relative risk of sustained disability progression compared to placebo. In addition, a significant reduction in annualized relapse rate was observed in patients treated with Aubagio 7 mg compared to placebo. The TOPIC study was designed to assess whether initiation of Aubagio in patients who experienced their first neurological symptoms suggestive of MS could prevent or delay a second clinical attack. In this study, the proportion of patients free of relapse was statistically significantly greater for Aubagio 14 mg and 7 mg, compared to placebo. Results of the TOPIC study were published in The Lancet Neurology in September.
08:06 EDTSNYMerck, Sanofi unit announce pediatric hexavalent vaccine BLA
Subscribe for More Information
07:47 EDTPFEPfizer less likely to renew Astra pursuit after Shire deal breakdown, FT says
Subscribe for More Information
07:32 EDTBIIBCubist names Perez CEO to succeed Bonney
Subscribe for More Information
07:19 EDTSNYIBC Life Sciences to hold a conference
Subscribe for More Information
07:15 EDTPFEAmerican Academy of Child & Adolescent Psychiatry to hold annual meeting
Subscribe for More Information
07:12 EDTPFECongress of Neurological Surgeons to hold annual meeting
Subscribe for More Information
07:11 EDTPFEAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
07:10 EDTPFE, SNYAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
07:02 EDTSNYRegeneron Sanofi begins dosing in Phase 3 study of dupilumab
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis, or AD, that is not adequately controlled with topical AD medications. LIBERTY AD CHRONOS, the first trial in the Phase 3 clinical program for dupilumab, is a randomized, double-blind, placebo-controlled, multi-national study with the primary objective of demonstrating the efficacy of dupilumab in adults with moderate to severe AD when administered concomitantly with topical corticosteroids through 16 weeks.
06:04 EDTBBRYAcacia Research subsidiary enters into agreement with BlackBerry
Acacia Research announced that its Cell and Network Selection subsidiary entered into an agreement with Blackberry Corporation and Blackberry Limited (BBRY). The agreement resolved litigation that was pending between Cell and Network Selection and Blackberry in the U.S. District Court for the Eastern District of Texas.
06:03 EDTBBRYBlackBerry implied volatility of 51 at lower end of index mean range
Subscribe for More Information
October 17, 2014
16:41 EDTPFEPfizer confirms FDA labeling approval for EMBEDA capsules
Pfizer announced that the FDA has approved an updated label for EMBEDA extended-release capsules, for oral use to include abuse-deterrence studies. The updated label states that EMBEDA has properties that are expected to reduce abuse via the oral and intranasal routes when crushed. However, abuse of EMBEDA by these routes is still possible. The updated label also includes data from a human abuse potential study of intravenous, or IV, morphine and naltrexone to simulate crushed EMBEDA. However, it is unknown whether the results with simulated crushed EMBEDA predict a reduction in abuse by the IV route until additional postmarketing data are available. EMBEDA is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Pfizer expects EMBEDA will be available in the U.S. in early 2015.
16:30 EDTPFEFDA approves new labeling from Embeda extended-release capsules
Subscribe for More Information
09:06 EDTSNYAmgen files patent infringement lawsuit against Sanofi, Regeneron
Amgen (AMGN) announced that it filed a lawsuit in the United States District Court of Delaware against Sanofi (SNY), Aventisub, formerly doing business as Aventis Pharmaceuticals, and Regeneron Pharmaceuticals (REGN) for patent infringement of U.S. Patent Numbers 8,563,698, 8,829,165, and 8,859,741. These patents, which are owned by Amgen, describe and claim monoclonal antibodies to proprotein convertase subtilisin/kexin type 9, or PCSK9. By its complaint, Amgen seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron's alirocumab, a monoclonal antibody targeting PCSK9. Sanofi and Regeneron recently announced that they have completed Phase 3 clinical trials on alirocumab and intend to pursue regulatory approval to market alirocumab in the U.S. Amgen previously announced submission of a Biologics License Application to the FDA for evolocumab, its own investigational human monoclonal antibody to PCSK9, for the treatment of high cholesterol, on Aug. 28.
06:46 EDTBBRYBlackBerry implied volatility of 55 at lower end of index mean range
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use